Literature DB >> 10096098

Acute/relapsing experimental autoimmune encephalomyelitis: induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation.

D Karussis1, U Vourka-Karussis, R Mizrachi-Koll, O Abramsky.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is an inducible autoimmune disease widely used as a model of the acute/relapsing stage of multiple sclerosis. We have previously shown that treatment of EAE-mice with high doses of cyclophosphamide (CY) (350 mg kg), followed by syngeneic bone marrow transplantation (SBMT), completely abrogates the clinical paralytic signs and even prevents the appearance of new relapses in the chronic-relapsing model of the disease. In the present study we examined whether this treatment protocol induces long term tolerance and whether this tolerance is antigen-specific. EAE was induced by immunization with spinal cord homogenate (MSCH) in complete Freund's adjuvant (CFA). The treatment with CY and SBMT was performed on day 6 post immunization. Treated and untreated mice were rechallenged with MSCH, or a non-relevant antigen (OVA) in CFA at various stages after the first paralytic attack. In contrast to previous data showing that animals recovering from acute EAE are usually refractory to re-induction of the disease, repeated injections of MSCH at different sites from the initial immunization, followed by i.v. injection of inactivated Bordetella bacteria, 2, 4 and 6 months after the initial EAE-induction, caused a severe and usually lethal relapse in all the untreated, control animals. Mice treated with CY and SBMT were resistant to all rechallenges with the same encephalitogenic inoculum. Following the second rechallenge, peripheral lymph node cells were examined in vitro for their proliferative responses to myelin antigens or to OVA. Lymphocytes obtained from CY+SBMT treated mice did not proliferate in vitro in response to myelin basic protein (MBP), but proliferated against OVA, when immunized with this antigen, after SBMT. Adoptive transfer of lymphocytes from tolerant mice to naive recipients did not transfer resistance to EAE-induction. Our results indicate that high doses of CY, followed by SBMT, induce long term antigen-specific tolerance presumably by a mechanism of clonal deletion or anergy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10096098     DOI: 10.1177/135245859900500104

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  10 in total

Review 1.  Aggressive multiple sclerosis-is there a role for stem cell transplantation?

Authors:  Eva Havrdova
Journal:  J Neurol       Date:  2005-09       Impact factor: 4.849

Review 2.  Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).

Authors:  Cris S Constantinescu; Nasr Farooqi; Kate O'Brien; Bruno Gran
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 3.  Immunologic therapy for secondary and primary progressive multiple sclerosis.

Authors:  L W Myers
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

Review 4.  Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale.

Authors:  Dimitrios Karussis; Panayiota Petrou
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

5.  High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.

Authors:  Richard A Nash; James D Bowen; Peter A McSweeney; Steven Z Pavletic; Kenneth R Maravilla; Man-soo Park; Jan Storek; Keith M Sullivan; Jinan Al-Omaishi; John R Corboy; John DiPersio; George E Georges; Theodore A Gooley; Leona A Holmberg; C Fred LeMaistre; Kate Ryan; Harry Openshaw; Julie Sunderhaus; Rainer Storb; Joseph Zunt; George H Kraft
Journal:  Blood       Date:  2003-05-22       Impact factor: 22.113

6.  The myelin basic protein gene is expressed in differentiated blood cell lineages and in hemopoietic progenitors.

Authors:  M C Marty; F Alliot; J Rutin; R Fritz; D Trisler; B Pessac
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

Review 7.  Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?

Authors:  Richard K Burt; Shimon Slavin; William H Burns; Alberto M Marmont
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.319

8.  Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results.

Authors:  J D Bowen; G H Kraft; A Wundes; Q Guan; K R Maravilla; T A Gooley; P A McSweeney; S Z Pavletic; H Openshaw; R Storb; M Wener; B A McLaughlin; G R Henstorf; R A Nash
Journal:  Bone Marrow Transplant       Date:  2011-11-07       Impact factor: 5.483

Review 9.  Vaccines, adjuvants and autoimmunity.

Authors:  Luísa Eça Guimarães; Britain Baker; Carlo Perricone; Yehuda Shoenfeld
Journal:  Pharmacol Res       Date:  2015-08-12       Impact factor: 7.658

10.  Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis.

Authors:  Kaja Kasarełło; Emilian Snarski; Dorota Sulejczak; Tomasz Ciesielski; Agnieszka Wiśniewska; Robert Wrzesień; Agnieszka Cudnoch-Jędrzejewska
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-06-28       Impact factor: 4.291

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.